Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2005
F. Stocchi 1, L. Vacca 1, G. Battaglia 1, P. Grassini 1, S Ruggirei 1, A. Thomas 2, M. Onofrj 2
Clinical evidence of efficacy for safinamide
1 IRCCS Neuromed, Pozzilli, Italy; 2 University G. DAnnunzio, Chieti, Italy 7th International Congress AD/PD 2005 Sorrento 9-12 March
T.C. Stummann, P. Salvati, R.G Fariello, L. Faravelli
The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons.
Eur J Pharmacol. 2005 Mar 14;510(3): 197-208.
C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, P. Salvati, RG Fariello
Safinamide: from molecular targets to a new antiparkinson drug
7th International Congress AD/PD 2005 Sorrento 9-12 March